Elvinix licenses Zealand Pharma GLP-1/gastrin portfolio for type 1 diabetes
The deal gives Elvinix dual-agonist peptides Zealand had developed, targeting beta-cell preservation in type 1 diabetes rather than weight loss.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 12:25 ETSource: allsci.com
The wire
- 01Elvinix acquired rights to Zealand Pharma's GLP-1/gastrin dual-agonist peptide portfolio for type 1 diabetes development.
- 02Redirects GLP-1 biology toward a disease-modifying goal in type 1 diabetes, a rare focus in a weight-loss-dominated field.
- 03Deal terms, development timelines and trial plans were not detailed in the report.
From the source
Read at news.google.comElvinix picks up Zealand's GLP-1/gastrin portfolio for type 1 diabetes development